Remove mymd-pharmaceuticals-announces-upcoming-presentation-of-preclinical-rheumatoid-arthritis-data-for-oral-tnf-�-inhibitor-mymd-1-at-the-society-of-toxicology-2023-annual-meeting
article thumbnail

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-? Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Medical Marijuana Program Connection

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. Read More